SCHEMBL5157945

SCHEMBL5157945

COc1ccc(-c2c(C(=O)N=CN(C)C)[nH]c3cc(OC)c(OC)cc23)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
ATM Q13315 1/20 0.55
MAP2 P11137 1/20 0.46
ALDH1A1 P00352 7/20 0.46
KDM4E B2RXH2 7/20 0.46
MAPT P10636 6/20 0.46
HPGD P15428 5/20 0.46
HTT P42858 2/20 0.45
POLB P06746 2/20 0.45
LMNA P02545 3/20 0.41
HSD17B10 Q99714 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
RAB9A P51151 1/20 0.41
GAA P10253 3/20 0.38
NPSR1 Q6W5P4 3/20 0.38
TDP1 Q9NUW8 1/20 0.38
USP2 O75604 1/20 0.38
TP53 P04637 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5425215 1.00 MEN1 (0.55) MEN1KMT2AATMMAP2ALDH1A1
SCHEMBL4591604 0.80 KDM4E (0.54) MEN1KMT2AMAP2ALDH1A1KDM4E
SCHEMBL4900969 0.79 MAP2 (0.70) MAP2ALDH1A1KDM4EMAPTHPGD
SCHEMBL5157162 0.79 MAPT (0.54) MEN1KMT2AMAP2ALDH1A1KDM4E
SCHEMBL5159252 0.76 KDM4E (0.63) MEN1KMT2AMAP2ALDH1A1KDM4E
SCHEMBL5427113 0.74 MAPT (0.53) MEN1KMT2AMAP2ALDH1A1KDM4E
SCHEMBL4601191 0.73 MCL1 (0.50) MEN1KMT2AMAP2ALDH1A1KDM4E
SCHEMBL5159528 0.71 KDM4E (0.56) MEN1KMT2AMAP2ALDH1A1KDM4E
SCHEMBL4885700 0.71 GPR35 (0.49) MEN1KMT2AATMMAP2ALDH1A1
SCHEMBL4592847 0.70 GPR35 (0.65) MEN1KMT2AMAP2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070248672-A1 Indole and Azaindole Derivatives with Antitumor Action NIKEM RESEARCH S.R.L. (IT) 2007-10-25 US disclosed
EP-1750687-A2 INDOLE AND AZAINDOLE DERIVATIVES WITH ANTITUMOR ACTION NIKEM RESEARCH S.R.L. (IT) 2007-02-14 EP disclosed
WO-2005105213-A2 INDOLE AND AZAINDOLE DERIVATIVES WITH ANTITUMOR ACTION NIKEM RESEARCH S.R.L. (IT) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070248672-A1 Indole and Azaindole Derivatives with Antitumor Action IDO1, IDO2, INMT MEN1 2173/4885KMT2A 195/4885ATM 850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.